Sleeping sickness, also known as African trypanosomiasis, is a parasitic disease caused by infection with Trypanosoma brucei parasites, transmitted through the bite of infected tsetse flies. The illness progresses through stages marked by fever, neurological disturbances, and eventually severe sleep cycle disruption.
The disease is endemic in 36 sub-Saharan African countries, primarily in rural areas with dense vegetation where tsetse flies thrive. Transmission occurs when a tsetse fly bites a human or animal, injecting the parasite into the bloodstream. Without treatment, the infection spreads to the central nervous system, leading to coma and death.
According to the World Health Organization (WHO), approximately 7,000 cases were reported globally in 2022, a significant decline from peak years. The reduction is attributed to targeted surveillance and treatment programs in high-risk zones. The WHO classifies the disease as a neglected tropical disease due to limited funding and research compared to other global health priorities.
Trypanosoma brucei exists in two forms: the slender form, which multiplies rapidly in the blood and lymphatic system, and the stumpy form, which is adapted for transmission to the tsetse fly. When a fly feeds on an infected host, it ingests the parasites, which then develop into procyclic forms in the fly's midgut.
After 10-14 days, the parasites migrate to the fly's salivary glands and change into metacyclic forms. When the fly bites another mammal, it injects these forms into the skin. The parasites enter the bloodstream and begin replicating, causing initial symptoms such as fever, headache, joint pain, and itching.
As the infection advances, the parasites cross the blood-brain barrier. This marks the onset of the second stage, characterized by neurological symptoms including confusion, poor coordination, and disrupted sleep patterns-hence the name "sleeping sickness." The disease can be fatal within months if untreated.
There are two main forms of African trypanosomiasis based on the parasite subspecies:
| Type | Parasite Subspecies | Transmission Area | Key Clinical Features |
|---|---|---|---|
| West African sleeping sickness | T. b. gambiense | West and Central Africa | Chronic progression over months to years; accounts for ~98% of cases |
| East African sleeping sickness | T. b. rhodesiense | Eastern and Southern Africa | Acute onset; progresses rapidly over weeks to months; higher fatality rate |
West African sleeping sickness is responsible for nearly all reported cases. It is often asymptomatic in early stages, making detection difficult. East African sleeping sickness tends to progress faster and is more likely to cause severe systemic reactions, including high fever and swelling of the lymph nodes.
A 2021 study published in *The Lancet Infectious Diseases* found that T. b. gambiense infections had a median incubation period of 3.2 months, while T. b. rhodesiense cases showed symptoms within 1-2 weeks of exposure. These differences influence screening protocols and treatment timing.
Many confuse sleeping sickness with other neurological disorders like encephalitis or dementia. Unlike those conditions, sleeping sickness is not contagious between humans. It cannot be passed through touch, food, or airborne routes. Only vector-borne transmission via tsetse flies is effective.
Another common error is assuming the disease causes excessive daytime sleepiness. While patients do exhibit altered sleep-wake cycles, they often suffer from insomnia at night and extreme fatigue during the day-symptoms that reflect brainstem dysfunction rather than simple tiredness.
In 2020, a 34-year-old farmer in the Bas-Uélé region of the Democratic Republic of the Congo developed persistent fever and swollen lymph nodes. He lived near a riverbank where tsetse flies were prevalent. After two weeks of worsening headaches and difficulty concentrating, he sought care at a local clinic.
Blood tests confirmed the presence of Trypanosoma brucei gambiense. Lumbar puncture revealed elevated white blood cells in cerebrospinal fluid, confirming stage 2 disease. He was treated with fexinidazole, a newer oral medication approved by the WHO in 2018 for stage 1 and 2 infections.
After 10 days of treatment, his symptoms resolved. Follow-up testing six months later showed no detectable parasites. His recovery highlights the effectiveness of early diagnosis and access to modern therapeutics, though challenges remain in remote regions with limited healthcare infrastructure.
Despite declining case numbers, sleeping sickness remains a public health concern in sub-Saharan Africa. The disease disproportionately affects impoverished populations who live near tsetse fly habitats and lack access to diagnostic tools.
Prevention focuses on reducing contact with tsetse flies through insecticide-treated clothing, bed nets, and environmental management. Control programs also include active screening in endemic zones and treating infected individuals promptly to stop transmission chains.
Today, sleeping sickness is treatable, but not curable in all cases. Some patients experience relapse or long-term cognitive deficits. Ongoing research aims to improve diagnostics, reduce treatment duration, and develop vaccines. Until then, early detection remains the most effective strategy against this debilitating disease.